ABSTRACT
Objective:To explore the construction of hospital-community-family multiple maintenance management model for Alzheimer′s disease (AD) population and its clinical intervention effect.Methods:Two hundred patients with AD admitted to the Second Affiliated Hospital of Nanchang University from January 2018 to December 2020 were selected as the research subjects, including 92 cases in control group and 108 cases in study group. The control group adopted the conventional management mode of hospital combined with family care. The study group adopted the hospital-community-family multiple maintenance management mode. The improvement of medication compliance, mental state, cognitive function and quality of life were compared between the two groups before intervention and six, nine and 12 months after intervention using neuropsychological scales.Results:Compared with before intervention (4.57±1.01 and 56.55±3.83), the scores of Morisky Medication Adherence Scale 8 (MMAS-8; 5.33±1.05, 5.84±1.17 and 5.91±1.24) and the World Health Organization Quality of Life Instrument, Short Form (WHOQOL-BREF; 59.23±3.43, 61.47±3.56 and 62.24±3.45) in the control group increased six, nine and 12 months after intervention ( t=5.003, 7.881, 8.037, 4.795, 8.823, 10.380, all P<0.05), while the scores of Montreal Cognitive Assessment (MoCA) Scale had no significant change. The scores of MMAS-8 (5.96±1.11, 7.13±1.09 and 7.15±1.11), MoCA (19.96±1.31, 20.36±1.47 and 20.42±1.52) and WHOQOL-BREF (62.76±3.52,65.25±3.43, and 65.87±3.56) in the study group increased six, nine and 12 months after intervention and were higher than those in the control group (MoCA: 19.03±1.48, 18.65±1.51 and 18.59±1.44; t=4.101, 8.064, 7.460, 4.713, 9.088, 8.693, 7.152, 7.633, 7.290, all P<0.05). There were significant differences between groups, time points and interaction between groups in the scores of MMAS-8, MoCA and WHOQOL-BREF. Conclusion:The construction of hospital-community-family multiple maintenance management model for AD patients has a positive effect on improving the quality of life and prognosis of AD patients, which is worthy of further promotion and application.